journal
MENU ▼
Read by QxMD icon Read
search

Journal of Oncology Pharmacy Practice

journal
https://www.readbyqxmd.com/read/27903792/clinical-effectiveness-of-bevacizumab-in-patients-with-recurrent-brain-tumours-a-population-based-evaluation
#1
REVIEW
Mário L de Lemos, Adeline Markarian, Esther Chan, Kimberly Schaff, Susan Walisser
BACKGROUND: Bevacizumab is an antiangiogenic agent active in patients with recurrent malignant gliomas. However, evidence for its clinical efficacy is relatively limited so that bevacizumab is approved for this indication in Canada and the United States, but not in the European Union. We reviewed the effectiveness of bevacizumab in patients with recurrent brain tumour using a large population database. METHODS: This was a retrospective, multicentre, study conducted at the BC Cancer Agency, a public cancer care organisation for the residents of the Canadian province of British Columbia...
November 30, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27895220/patient-perspectives-on-the-barriers-associated-with-medication-adherence-to-oral-chemotherapy
#2
Benyam Muluneh, Allison Deal, Maurice D Alexander, Meredith D Keisler, Janell M Markey, Jennifer M Neal, Stephen Bernard, John Valgus, Lynn G Dressler
PURPOSE: Appropriate use of oral chemotherapy is a challenge for patients and clinicians. The purpose of this study was to analyze cancer patients' use of oral chemotherapies and identify opportunities to improve adherence. METHODS: We developed a 30-question survey to address frequency and reasons for reducing/skipping doses; sources of information for oral chemotherapy use; perceived importance of food-drug effects; and ease of understanding labeling directions...
November 28, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27872331/systemic-hypersensitivity-to-fosaprepitant-a-report-of-two-cases
#3
Allison Baxley, Zoe Lee, Patrick Medina
Fosaprepitant is a widely administered antiemetic used mainly for moderately to highly emetogenic chemotherapy. Local injection site reactions are the most common type of infusion reaction reported from fosaprepitant. At our institution, two separate patients have experienced systemic hypersensitivity reactions to their infusions of fosaprepitant. We report a review of the literature and the details of these reactions.
November 21, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27856924/prevention-of-carboplatin-induced-hypersensitivity-reactions-in-women-with-ovarian-cancer
#4
Katarzyna J Jerzak, Shaidah Deghan Manshadi, Pamela Ng, Manjula Maganti, Jeanna M McCuaig, Marcus Bulter, Amit Oza, Helen J Mackay
BACKGROUND: Carboplatin-based chemotherapy offers high response rates and improved overall survival for women with epithelial ovarian cancer, but its use is limited by the occurrence of hypersensitivity reactions. To evaluate the efficacy of prophylactic diphenhydramine for hypersensitivity reaction prevention, we reviewed the incidence of hypersensitivity reactions and identified patients at high risk of hypersensitivity reactions. METHODS: Women receiving ≥6 cycles of carboplatin-based chemotherapy for epithelial ovarian cancer were identified from our institutional database at the Princess Margaret Cancer Centre...
November 17, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27856923/evaluation-of-thromboembolic-events-in-cancer-patients-receiving-bevacizumab-according-to-the-japanese-adverse-drug-event-report-database
#5
Chikako Matsumura, Yugo Chisaki, Satoko Sakimoto, Honoka Sakae, Yoshitaka Yano
PURPOSE: We aimed to examine the risk factors, time of onset, incidence rates, and outcomes of thromboembolic events induced by bevacizumab in patients with cancer using the Japanese Adverse Drug Event Report (JADER) database of the Pharmaceuticals and Medical Devices Agency. METHODS: Adverse event data recorded in the JADER database between January 2004 and January 2015 were used. After screening the data using the generic drug name bevacizumab, patient data were classified into two groups by age and five groups by cancer type...
November 17, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27856922/surface-contamination-of-hazardous-drug-pharmacy-storage-bins-and-pharmacy-distributor-shipping-containers
#6
Kimberly A Redic, Kayleen Fang, Catherine Christen, Bruce W Chaffee
PURPOSE: This study was conducted to determine whether there is contamination on exterior drug packaging using shipping totes from the distributor and carousel storage bins as surrogate markers of external packaging contamination. METHODS: A two-part study was conducted to measure the presence of 5-fluorouracil, ifosfamide, cyclophosphamide, docetaxel and paclitaxel using surrogate markers for external drug packaging. In Part I, 10 drug distributor shipping totes designated for transport of hazardous drugs provided a snapshot view of contamination from regular use and transit in and out of the pharmacy...
November 17, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27856921/lenvatinib-a-multikinase-inhibitor-for-radioiodine-refractory-differentiated-thyroid-cancer
#7
REVIEW
Yvonne Hewett, Subash Ghimire, Bilal Farooqi, Binay K Shah
Lenvatinib, an oral multikinase inhibitor, was approved by the US Food and Drug Administration in February 2015. In a pivotal phase III study of 392 patients with progressive radioiodine-refractory thyroid cancer, the overall response rate of patients receiving lenvatinib was 64.8%, with complete response in four patients. The median progression-free survival was 18.3 months in the lenvatinib arm versus 3.6 months in patients receiving placebo. Median overall survival was not reached in either arm. Lenvatinib is a promising new treatment for patients with radioiodine (iodine-131)-refractory differentiated thyroid cancer...
November 17, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27837044/development-of-a-systematic-approach-to-pharmaceutical-industry-s-patient-assistance-programs-on-accessing-unfunded-cancer-drugs
#8
Victoria Kletas, Mario de Lemos
BACKGROUND: New oncology drugs usually become commercially available several months before the funding decisions are made by provincial public payers. Increasingly, patient assistance programs are being set up by pharmaceutical companies in order to facilitate access of their new cancer drugs before public funding decisions are finalized. We discovered that there is a need to keep this information up to date and available in a central repository, thus we have created a centralized patient assistance chart for use by all who require information on accessing unfunded drugs in our province...
November 10, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27799609/supratherapeutic-inr-resulting-from-the-initiation-of-warfarin-in-a-patient-receiving-axitinib
#9
Brian Primeaux, Bradley Burton, Stephanie Shuey
Axitinib is a vascular endothelial growth factor receptor inhibitor indicated for advanced renal cell cancer after failure of one prior systemic therapy. We report a case where a patient receiving axitinib experienced a supratherapeutic INR soon after initiation of an age-appropriate warfarin dose. We propose two possible mechanisms for this interaction, including competitive protein binding and decreased metabolism. Close INR monitoring and dose adjustments of warfarin may be necessary in patients receiving concomitant axitinib and warfarin in order to decrease the risks associated with this interaction...
October 31, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27799608/multicenter-study-of-environmental-contamination-with-cyclophosphamide-ifosfamide-and-methotrexate-in-48-canadian-hospitals
#10
Céline Poupeau, Cynthia Tanguay, Nicolas J Caron, Jean-François Bussières
CONTEXT: Oncology workers are occupationally exposed to antineoplastic drugs. This exposure can induce adverse health effects. In order to reduce their exposure, contamination on surfaces should be kept as low as possible. OBJECTIVES: To monitor environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in oncology pharmacy and patient care areas in Canadian hospitals. To describe the impact of some factors that may limit contamination. METHODS: This is a descriptive study...
October 31, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27799607/adherence-with-capecitabine-a-population-based-analysis-based-on-prescription-refill-data
#11
Laurel Kovacic, Neil de Haan, Mário L de Lemos, Kimberly Schaff, Susan Walisser
BACKGROUND: Patient adherence is important with the increasing use of oral anticancer drugs. Recent studies reported different capecitabine adherence rates based on self-reporting and microelectronic monitoring of the medication bottle. Patient's awareness of being monitored may confound these results. Prescription records provide a larger and more objective dataset for adherence investigation. We report the use of computer algorithm and manual review of prescription and medical documentation to determine the rate of capecitabine adherence...
October 31, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27799606/successful-reintroduction-of-blinatumomab-in-a-patient-with-relapsed-refractory-acute-lymphoblastic-leukemia-following-grade-4-cytokine-release-syndrome
#12
Bernard L Marini, Yihan Sun, Patrick W Burke, Anthony J Perissinotti
Relapsed/refractory acute lymphoblastic leukemia poses a clinical challenge due to its poor prognosis and lack of effective treatment. Blinatumomab, a novel immunotherapy, has demonstrated excellent efficacy in relapsed/refractory acute lymphoblastic leukemia; however, life-threatening toxicities such as cytokine release syndrome have been reported in pivotal clinical trials. In this report, we describe the safe reintroduction of blinatumomab in an adult patient with relapsed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia after experiencing grade 4 blinatumomab-induced cytokine release syndrome using a unique dosing strategy and a very diligent monitoring approach...
October 31, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27760811/cost-savings-analysis-and-toxicity-audit-of-a-bevacizumab-dose-rounding-policy-at-a-community-cancer-center
#13
Donald C Moore, Gary Neal McVey
PURPOSE: To evaluate the potential cost savings incurred from a policy to round doses of bevacizumab to the nearest vial size. Secondarily, to determine differences in rates of adverse events between patients who had their doses rounded up compared with those who had doses rounded down. METHODS: This study is a retrospective chart review of all patients who received at least one rounded dose of bevacizumab over a period of 22 months. Doses of bevacizumab were calculated based on actual body weight...
October 19, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27824587/failure-to-achieve-therapeutic-levels-with-high-dose-posaconazole-tablets-potentially-due-to-enhanced-clearance
#14
Sam Maleki, Carmela Corallo, John Coutsouvelis, Jasmine Singh
AIM: To describe a case of persistent sub-therapeutic posaconazole levels in setting of salvage chemotherapy for relapsed acute myeloid leukemia. CASE DETAILS: A 57-year-old male was admitted for the management of relapsed acute myeloid leukemia and ongoing pulmonary aspergillosis. While continuing on posaconazole tablet 300 mg daily, he received a course of salvage chemotherapy. The initial steady state posaconazole trough level was therapeutic at 0.84 mg/L (target >0...
October 18, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27824586/persistently-curly-hair-phenotype-with-the-use-of-nivolumab-for-squamous-cell-lung-cancer
#15
Constantin A Dasanu, Scott M Lippman, Steven C Plaxe
Increasing use of programmed cell death protein 1/programmed cell death protein 1 ligand inhibition for the treatment of patients with various malignancies such as advanced lung cancer, kidney cancer, and melanoma has resulted in valuable clinical responses, along with the occurrence of new and often puzzling side effects. Known cutaneous effects of CTLA4 and programmed cell death protein 1/programmed cell death protein 1 ligand inhibitors include generalized pruritus, vitiligo, maculopapular lesions, and lichenoid skin eruptions...
October 18, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27753628/study-of-cases-of-abiraterone-discontinuation-due-to-toxicity-in-pre-chemotherapy-after-1-year-s-experience
#16
Luis Ramudo Cela, Jesús Balea Filgueiras, José Ramón Vizoso Hermida, Isabel Martín Herranz
Abiraterone acetate is a potent and irreversible inhibitor of cytochrome p450 17A1 that suppresses androgen synthesis. It is approved for chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer. We describe the protocol for use of abiraterone in metastatic castration-resistant prostate cancer chemotherapy naive patients has been implanted in our centre and we review the cases of those patients whose adverse effects have forced the discontinuation of treatment. The side effects fit the safety profile of abiraterone, speed of their appearance and severity indicate that you should perform a thorough follow-up of these patients especially in the early phases of treatment...
October 16, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27738095/ceritinib-a-primer-for-pharmacists
#17
Trang H Au, Courtney C Cavalieri, David D Stenehjem
Clinical pharmacists are important contributors to the care of patients with cancer; it is therefore critical for oncology clinical pharmacists to stay current with new anticancer therapies. This review summarizes the epidemiology and pathogenesis of non-small cell lung cancer, including the most common genetic alterations, as well as the mechanism of action, clinical development, pharmacodynamics and pharmacokinetics of the anaplastic lymphoma kinase inhibitor ceritinib for the treatment of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer...
October 13, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27733666/the-impacts-of-a-pharmacist-managed-outpatient-clinic-and-chemotherapy-directed-electronic-order-sets-for-monitoring-oral-chemotherapy
#18
Brandon Battis, Linda Clifford, Mostaqul Huq, Edrick Pejoro, Scott Mambourg
OBJECTIVES: Patients treated with oral chemotherapy appear to have less contact with the treating providers. As a result, safety, adherence, medication therapy monitoring, and timely follow-up may be compromised. The trend of treating cancer with oral chemotherapy agents is on the rise. However, standard clinical guidance is still lacking for prescribing, monitoring, patient education, and follow-up of patients on oral chemotherapy across the healthcare settings. The purpose of this project is to establish an oral chemotherapy monitoring clinic, to create drug and lab specific provider order sets for prescribing and lab monitoring, and ultimately to ensure safe and effective treatment of the veterans we serve...
October 12, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27708192/romidepsin-associated-cardiac-toxicity-and-ecg-changes-a-case-report-and-review-of-the-literature
#19
Zachary T Rivers, Drew R Oostra, James S Westholder, Gregory M Vercellotti
BACKGROUND: Romidepsin is a novel histone deacetylase inhibitor that is approved for the treatment of cutaneous and peripheral T-cell lymphoma in patients who have had at least one prior therapy. Romidepsin is generally well tolerated, though it comes with a risk of cardiac toxicities. OBJECTIVE: We report a case of electrocardiogram changes in a 64-year-old male with enteropathy-associated T-cell lymphoma, type 2, treated with salvage romidepsin therapy who relapsed after non-myeloablative allogeneic sibling peripheral blood stem cell transplant...
October 5, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27682600/impact-of-pharmacist-interventions-on-cost-avoidance-in-an-ambulatory-cancer-center
#20
Laura A Randolph, Cheri K Walker, Ann T Nguyen, Subi R Zachariah
OBJECTIVE: To provide a foundation to justify the presence of a full-time clinical pharmacist in the ambulatory cancer center in addition to an existing centralized pharmacist through cost avoidance calculation and patient and staff satisfaction surveys. METHODS: The prospective, pilot study took place in an ambulatory cancer center over four weeks in 2014. Cost avoidance values were assigned to interventions performed by a pharmacy resident, who was present in the ambulatory cancer center during clinic hours, along with a centralized oncology pharmacist routinely working with the cancer center...
September 27, 2016: Journal of Oncology Pharmacy Practice
journal
journal
32324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"